SITC

HCW Biologics Reports Third Quarter 2023 Financial Results And Recent Business Highlights

Retrieved on: 
Tuesday, November 14, 2023
Letter of recommendation, Principal, Sale, Prejudice, Gynecologic Oncology (journal), University, IND, Bank statement, Gynaecology, JAMS, Loan agreement, Clinical trial, Patient, Insurance, Research, Division, Immunotherapy, G&A, TGF, District court, Ovarian cancer, Human, SITC, R, Loss, Court, Society, Professor, Notifiable disease, Inflammation, DL2, Pharmaceutical industry, Medical imaging, Vaccine, Cryptocurrency, Cancer, Liver, Obstetrics

MIRAMAR, Fla., Nov. 14, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its third quarter ended September 30, 2023.

Key Points: 
  • MIRAMAR, Fla., Nov. 14, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its third quarter ended September 30, 2023.
  • We are pleased to see the consistency of results in humans with those that we saw in our preclinical animal studies.
  • Third Quarter 2023 Financial Results:
    Revenues: Revenues for the quarter ended September 30, 2022 and 2023 were $1.8 million and $853,102, respectively.
  • Revenues for the nine months ended September 30, 2022 and 2023 were $5.4 million and $1.5 million, respectively.

Molecular Partners to Present on DARPin Oncology Innovations at Protein & Antibody Engineering Summit Europe (PEGS)

Retrieved on: 
Tuesday, November 14, 2023
DARPin, RDT, Immune system, Senior, Tetra, Service provider, ASH, CD70, CD40, Patient, Tumor microenvironment, Immunotherapy, Neoplasm, Therapy, FAP, Exposition, Novartis, CD33, Cancer, Trial of the century, SITC, Toxic epidermal necrolysis, Partnership, AML, Society, Molecular Partners, Myelodysplastic syndrome, CD123, Cell, CD3, Medical imaging, Vaccine, Research, CONCORD

The presentation will focus on the multiple ways Molecular Partners has designed DARPins to activate the immune system against cancer only under certain conditions.

Key Points: 
  • The presentation will focus on the multiple ways Molecular Partners has designed DARPins to activate the immune system against cancer only under certain conditions.
  • This conditional activation is intended to focus immune attack more specifically against tumor cells and minimize damage to healthy cells, a major challenge for current oncology drugs and development efforts.
  • The SWITCH-DARPin platform, a versatile novel DARPin design for conditionally triggering an immune cell attack only in the presence of defined tumor antigens.
  • The portfolio of RDT candidates represent a unique delivery system for radioactive payloads to solid tumors and has significantly expanded the company’s work in oncology therapeutics.

Nouscom Raises €67.5 million ($72 million) in Oversubscribed Series C Financing Round

Retrieved on: 
Tuesday, November 14, 2023
Cancer, Merck Group, Completion, Risk, Patient, Investment, Partner, Vaccine, Science, Biotechnology, Immunotherapy, Independent, Series, Hereditary nonpolyposis colorectal cancer, SITC, Affirmative action, Environment, Pharmaceutical industry, Andera-ye Olya, Bpifrance

BASEL, Switzerland – 14th November 2023 - Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vector-based cancer vaccines targeting neoantigens, today announced the completion of its oversubscribed Series C equity financing raising €67.5 million ($72 million) from a syndicate of renowned international healthcare investors.

Key Points: 
  • BASEL, Switzerland – 14th November 2023 - Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vector-based cancer vaccines targeting neoantigens, today announced the completion of its oversubscribed Series C equity financing raising €67.5 million ($72 million) from a syndicate of renowned international healthcare investors.
  • Concurrent with the financing, representatives from Andera Partners, Bpifrance and M Ventures have joined the Nouscom Board of Directors.
  • Dr. Marina Udier, Chief Executive Officer of Nouscom, said: “This oversubscribed financing, in what is a challenging environment for all biotech companies, is testament to the faith that new and existing investors place in Nouscom and our best-in-class technology.
  • We are excited to support the company to continue bringing these innovative candidates closer to patients.”

Senti Bio Announces Third Quarter 2023 Results and Pipeline Updates

Retrieved on: 
Monday, November 13, 2023
Sale, Research, Annual general meeting, SAN, Prevalence, Therapy, IND, Investment, Liver cancer, Biotechnology, Patient, Gene, GPC3, FDA, Immunotherapy, Neoplasm, Investigational New Drug, Celeste Nelson, SNTI, Cancer, SITC, CGMP, CMC, AML, Doctor of Philosophy, Synthetic biology, HCC, Society, Pharmaceutical industry, Vaccine, MD, Senti Aur Mental

SOUTH SAN FRANCISCO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported financial results for the third quarter of 2023.

Key Points: 
  • “The third quarter was highly productive for Senti as we continued advancing SENTI-202 towards IND clearance and further developed our platform technology,” said Timothy Lu, MD, PhD, Chief Executive Officer and Co-Founder of Senti Bio.
  • Through this collaboration, Celest will lead clinical development, operations, and manufacturing for the advancement of SENTI-301A with technical support from Senti Bio.
  • Approximately 35% of Senti Bio’s employees transitioned from Senti Bio to GeneFab, which will support the clinical manufacturing of Senti Bio’s chimeric antigen receptor natural killer (CAR-NK) programs, including SENTI-202.
  • As of September 30, 2023, Senti Bio held cash, cash equivalents and short-term investments of $39.4 million.

Beyond Air® Reports Financial Results for Second Quarter of Fiscal Year 2024

Retrieved on: 
Monday, November 13, 2023
VCAP, Nontuberculous mycobacteria, AARC, Fiscal year, Conference call, Atmosphere of Earth, American Academy, DSM-IV codes, Cancer, Patient, Research, NTM, Calendar, FDA, Immunotherapy, Vizient, Inc., Conference, B cell, UNO, SITC, Survival, Society, PMA, AACR, Pharmaceutical industry, Cryptocurrency, Vaccine, Payment card

“Market confidence in our superior LungFit PH technology continues to grow along with our market penetration and opportunities.

Key Points: 
  • “Market confidence in our superior LungFit PH technology continues to grow along with our market penetration and opportunities.
  • I am proud of our progress and want to thank our customers who gave us the opportunity to succeed over the past year.
  • Aside from these one-time payments, cash burn in the quarter was $10.1 million which is in line with our guidance of approximately $10 million per quarter.
  • As of September 30, 2023, the Company had cash, restricted cash, cash equivalents and marketable securities of $43.9 million.

IO Biotech Announces 2023 Third Quarter Results

Retrieved on: 
Monday, November 13, 2023
SCCHN, Neck, Research, Annual general meeting, Therapy, Head, CFO, Amgen, ESMO, Patient, IDO1, PFS, Vaccine, Pembrolizumab, Immunotherapy, Conference, ORR, Melanoma, MD, SITC, Lung cancer, Doctor of Philosophy, Congress, Neoplasm, Society, WCLC, Pharmaceutical industry, Cryptocurrency

“Our focus for 2023 has been to successfully execute multiple clinical trials for our novel, investigational therapeutic cancer vaccine, IO102-IO103.

Key Points: 
  • “Our focus for 2023 has been to successfully execute multiple clinical trials for our novel, investigational therapeutic cancer vaccine, IO102-IO103.
  • Encouraging preliminary data from this basket trial were presented at the IASLC 2023 World Conference on Lung Cancer (WCLC) in September 2023 and at the ESMO Congress in October 2023.
  • General and administrative expenses were consistent at $5.8 million for the three months ended September 30, 2023 and 2022, respectively.
  • Cash and cash equivalents as of September 30, 2023, were $165.5 million, compared to $142.6 million at December 31, 2022.

RAPT Therapeutics Reports Third Quarter 2023 Financial Results

Retrieved on: 
Monday, November 13, 2023
RAPT, Research, Therapy, SAN, Patient, Inflammation, Lung cancer, Atopic dermatitis, SITC, Nine Months, Asthma, Pharmaceutical industry, Clothing, Airline, Cryptocurrency

SOUTH SAN FRANCISCO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today reported financial results for the third quarter and the nine months ended September 30, 2023.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today reported financial results for the third quarter and the nine months ended September 30, 2023.
  • Our current cash balance remains strong and we expect it to support our planned operations through mid-2025.”
    Financial Results for the Third Quarter and the Nine Months Ended September 30, 2023
    Third Quarter Ended September 30, 2023
    Net loss for the third quarter of 2023 was $31.4 million, compared to $21.2 million for the third quarter of 2022.
  • Research and development expenses for the third quarter of 2023 were $27.0 million, compared to $16.6 million for the same period in 2022.
  • General and administrative expenses for the third quarter of 2023 were $6.9 million, compared to $5.1 million for the same period in 2022.

Theriva™ Biologics Reports Third Quarter 2023 Operational Highlights and Financial Results

Retrieved on: 
Monday, November 13, 2023
Durvalumab, Neck, Research, NYSE, Shield, GMP, Safety, Telephone, Head, Conference call, Clinical trial, ESMO, HCT, Patient, FDA, Cancer, VCN, Therapy, Conference, University, SITC, Survival, Congress, CPS, KOL, ICO, Travel, University of Pennsylvania, Pharmaceutical industry, Cryptocurrency, PDAC

ET -

Key Points: 
  • ET -
    ROCKVILLE, Md., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today reported financial results for the third quarter ended September 30, 2023, and provided a corporate update.
  • Third Quarter Ended September 30, 2023 Financial Results
    General and administrative expenses decreased to $212,000 for the three months ended September 30, 2023, from $2.4 million for the three months ended September 30, 2022.
  • Theriva Biologics will host a conference call on Monday, November 13, 2023, at 8:30 a.m.
  • ET to discuss its financial results for the quarter ended September 30, 2023 and provide a corporate update.

Achilles Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights

Retrieved on: 
Monday, November 13, 2023
ACHL, Annual general meeting, Therapy, Gene, Patient, Cell, Research, ESGCT, G&A, Immunotherapy, CD4, Blood, Conference, CD8, Cancer, Vaccine, SITC, R, Congress, Society, TIL, NSCLC, Pharmaceutical industry, Cryptocurrency, CNET

LONDON, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today announced its financial results for the quarter ended September 30, 2023, and recent business highlights.

Key Points: 
  • LONDON, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today announced its financial results for the quarter ended September 30, 2023, and recent business highlights.
  • Research and development (R&D) expenses: R&D expenses were $14.7 million for the third quarter ended September 30, 2023, an increase of $4.1 million compared to $10.6 million for the third quarter ended September 30, 2022.
  • General and administrative (G&A) expenses: G&A expenses were $4.4 million for the third quarter ended September 30, 2023, a decrease of $1.0 million compared to $5.4 million for the third quarter ended September 30, 2022.
  • Net loss: Net loss for the third quarter ended September 30, 2023, was $16.7 million or $0.42 per share compared to $12.5 million or $0.32 per share for the third quarter ended September 30, 2022.

Turnstone Biologics Corp. Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights

Retrieved on: 
Friday, November 10, 2023
Uveal melanoma, Selection, Colorectal cancer, Investment, Breast cancer, Administration, Patient, Piper Sandler Companies, Melanoma, Immunotherapy, Takeda Oncology, Conference, IPO, SITC, R, Research and development, Coronavirus Scientific Advisory Board, Physician, TIL, Research institute, Pharmaceutical industry, Turnstone

SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today reported financial results for the quarter ended September 30, 2023, and provided recent business highlights.

Key Points: 
  • In October 2023, Turnstone appointed Jeffrey S. Weber, M.D., Ph.D., to its Scientific Advisory Board.
  • In July 2023, Turnstone priced its initial public offering (IPO) at $12.00 per share.
  • Cash, Cash Equivalents and Short-Term Investments: As of September 30, 2023, cash, cash equivalents and short-term investments were $109.1 million.
  • Net Loss: Net loss for the three months ended September 30, 2023, was $17.3 million, compared to net loss of $16.2 million for the third quarter of 2022.